Equities Analysts Issue Forecasts for PRQR FY2025 Earnings

ProQR Therapeutics (NASDAQ:PRQR) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of ProQR Therapeutics in a research report issued to clients and investors on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse forecasts that the biopharmaceutical company will post earnings of ($0.39) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $8.00 price objective on the stock. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.31) per share.

A number of other brokerages have also recently issued reports on PRQR. Oppenheimer started coverage on ProQR Therapeutics in a report on Friday, January 10th. They issued an “outperform” rating and a $15.00 target price on the stock. Evercore ISI began coverage on shares of ProQR Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $5.00 price objective on the stock. HC Wainwright lifted their price target on ProQR Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, March 14th. Citigroup raised shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price target for the company in a research report on Monday, March 10th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $4.00 price objective on shares of ProQR Therapeutics in a research report on Friday, March 14th. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.75.

ProQR Therapeutics Stock Up 3.6 %

Shares of ProQR Therapeutics stock opened at $1.72 on Thursday. The business has a fifty day simple moving average of $1.56 and a 200-day simple moving average of $2.49. The firm has a market cap of $180.97 million, a price-to-earnings ratio of -5.38 and a beta of 0.25. ProQR Therapeutics has a fifty-two week low of $1.07 and a fifty-two week high of $4.62.

Institutional Investors Weigh In On ProQR Therapeutics

Large investors have recently bought and sold shares of the business. Jane Street Group LLC bought a new position in ProQR Therapeutics during the fourth quarter valued at about $30,000. Invesco Ltd. bought a new stake in ProQR Therapeutics during the fourth quarter worth approximately $32,000. Alpine Global Management LLC acquired a new position in ProQR Therapeutics during the fourth quarter valued at approximately $39,000. Two Sigma Securities LLC acquired a new position in ProQR Therapeutics during the fourth quarter valued at approximately $40,000. Finally, Vontobel Holding Ltd. bought a new position in shares of ProQR Therapeutics in the first quarter valued at approximately $48,000. 32.65% of the stock is currently owned by institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).